Product image of Zynlonta (Loncastuximab Tesirine) supplied by GNH India

Zynlonta

Active Ingredient:
Loncastuximab Tesirine
Origin:
EU

Zynlonta (Loncastuximab Tesirine)

Zynlonta (loncastuximab tesirine) is an intravenous therapy for certain blood cancers, designed to target CD19-positive cells. This prescription medication is administered in clinical settings for relapsed or refractory conditions. Always consult a healthcare provider for suitability. Short version: Zynlonta is an IV therapy for relapsed or refractory blood cancers targeting CD19-positive cells.

Manufacturer / TM Owner

Swedish Orphan Biovitrum Ab (Publ)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zynlonta is used to treat relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after at least two prior therapies. It is specifically indicated for adults whose cancer expresses the CD19 protein. Patients often seek options like this when standard treatments have not been effective. It is not a first-line therapy and is reserved for advanced cases.

Side Effects

  • Zynlonta works by targeting CD19-positive cancer cells, helping to reduce tumor size in eligible patients. Common effects may include changes in blood cell counts, fatigue, or swelling at the infusion site. Some patients report mild nausea or skin reactions during treatment. These effects vary and should be monitored by a healthcare professional.

Precautions & Warnings

  • Zynlonta is administered under medical supervision due to potential serious side effects. Patients should disclose all medications and conditions to their provider before starting treatment. Regular blood tests are typically required to monitor for complications. Avoiding infections and staying hydrated can support treatment tolerance.

Avoid Interactions

  • Zynlonta may interact with other drugs that affect liver enzymes, such as certain antifungals or anticonvulsants. Live vaccines should be avoided during treatment. Strong CYP3A inhibitors or inducers can alter loncastuximab levels, requiring dose adjustments. Always inform your doctor about all medications, including over-the-counter and herbal products.

Frequently Asked Questions

Zynlonta is used to treat relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after at least two prior therapies.

Zynlonta is given as an intravenous infusion in a clinical setting under healthcare supervision.

Common effects may include changes in blood cell counts, fatigue, nausea, or skin reactions at the infusion site.

Zynlonta may interact with certain drugs; always inform your doctor about all medications you are taking before starting treatment.

No, Zynlonta is reserved for relapsed or refractory cases after at least two prior therapies have been tried.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Loncastuximab Tesirine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT